Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saha...(48 hours between the onset of symptoms a...),Health

Date:12/2/2008

48 hours between the onset of symptoms and death. Preventing malaria-related death in endemic areas involves ensuring that children are rapidly treated with an effective anti-malarial, and that they comply with the full course of treatment.

Now that most endemic countries have switched their drug policies to highly effective artemisinin-based combination therapies, the primary constraint to effective treatment in children is access at community level, especially as almost half of all malaria cases in Africa are treated at home. This problem was recently highlighted in the World Malaria Report 2008 from the WHO, which states, "The procurement of anti-malarial medicines through public health services increased sharply between 2001 and 2006, but access to treatment, especially of artemisinin-based combination therapy, was inadequate in all countries surveyed in 2006."

PSI is one of the world's leading malaria control agencies. Since January 2005 PSI has delivered over 40 million insecticide-treated mosquito nets and over 12.5 million doses of anti-malarial medication. As the international community nears the deadlines for the Millennium Development Goals and Abuja Targets, PSI stands ready to accelerate the scaling up of these interventions to increase and sustain malaria control activities in 32 malaria endemic countries.

TDR, the Special Programme for Research and Training in Tropical Diseases, is a global program of scientific collaboration established in 1975, sponsored by the United Nations Children's Fund, United Nations Development Programme, the World Bank and the World Health Organization. Its focus is research into diseases of the poor -- both improving and developing new approaches, and expanding research capacity in the countries where the diseases are prevalent.

Child survival is a priority for CIDA. Since malaria is the leading cause of death in African children und
'/>"/>

SOURCE Population Services International Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
2. Study finds Canadas supervised injection facility cost-effective
3. Integrated Beverage Group Launches Childrens Throat Cooler(R) in Canada
4. New Acticoat(TM) Silver Coated Anti-microbial Barrier Dressing Receives Regulatory Approval from Health Canada
5. NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
6. Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada
7. Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
8. Worlds First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
9. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
10. Colds and flu cut by one-third in study of Canadas top cold fighter in vaccinated seniors
11. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada